Brain imaging investigation of chemotherapy-induced neurocognitive changes

Cognition and Cancer

Volumn , Issue , 2008, Pages 19-32

  McDonald, Brenna C ^a   Saykin, Andrew J ^a   Ahles, Tim A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77349124166     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545900.004     Document Type: Chapter

References (78)

1. Ahles TA, Saykin AJ (2002). Breast cancer chemotherapy- related cognitive dysfunction. Clin Breast Cancer 3(3): 84-90.
2. Ahles TA, Saykin AJ (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Rev 7(3): 192-201.
3. Ahles TA, Silberfarb PM, et al. (1998). Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol 16(5): 195-460.
4. Ahles TA, Saykin AJ, et al. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20(2): 485-493.
5. Allen JC, Rosen G, et al. (1980). Leukoencephalopa- thy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 64(12): 126-173.
6. Anderson-Hanley C, Sherman ML, et al. (2003). Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. JInt Neuropsy- cholSoc 9(7): 967-982.
7. Ashburner J, Friston KF (2000). Voxel-based morphometry -the methods. NeuroImage 11(6 Pt 1): 805-821.
8. Ashburner J, Friston KJ (2001). Why voxel-based morphometry should be used. NeuroImage 14(6): 1238-1243.
9. Bandettini PA, Wong EC (1997). Magnetic resonance imaging of human brain function. Principles, practicalities, and possibilities. Neurosurg Clin North Am 8(3): 345-371.
10. Bandettini PA, Jesmanowicz A, et al. (1993). Processing strategies for time-course data sets in functional MRI of the human brain. MagnResMed 30(2): 161-173.
11. Basser PJ, Mattiello J, et al. (1994). MR diffusion tensor spectroscopy and imaging. BiophysJ 66(1): 259-267.
12. Belliveau JW, Kwong KK, et al. (1992). Magnetic resonance imaging mapping of brain function. Human visual cortex. Invest Radiol 27(Suppl 2): S59-S65.
13. Brezden CB, Phillips KA, et al. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18(14): 2695-2701.
14. Brown MS, Simon JH, et al. (1995). MR and proton spectroscopy of white matter disease induced by high- dose chemotherapy with bone marrow transplant in advanced breast carcinoma. AJNR Am J Neuroradiol 16(10): 2013-2020.
15. Brown MS, Stemmer SM, et al. (1998). White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. AJNR Am J Neuroradiol 19(2): 217-221.
16. Castellon SA, Ganz PA, et al. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26(7): 955-969.
17. Castellon SA, Silverman DHS, et al. (2005). Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat 92(3): 199-206.
18. Ciesielski KT, Lesnik PG, et al. (1999). MRI morphometry of mammillary bodies, caudate nuclei, and prefrontal cortices after chemotherapy for childhood leukemia: multivariate models of early and late developing memory subsystems. Behav Neurosci 113(3): 439-450.
19. D’Esposito M, Zarahn E, et al. (1999). The effect of normal aging on the coupling of neural activity to the bold hemodynamic response. NeuroImage 10(1): 6-14.
20. Donovan KA, Small BJ, et al. (2005). Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 104(11): 2499-2507.
21. Ebner F, Ranner G, et al. (1989). MR findings in methotrexate-induced CNS abnormalities. Am J Roentgenol 153(6): 1283-1288.
22. Eichbaum MHR, Schneeweiss A, et al. (2007). Smaller regional volumes of gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109(1): 146-156.
23. Ferguson RJ, Ahles TA (2003). Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep 3: 215-222.
24. Ferguson RJ, McDonald BC, et al. (2007). Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 25(25): 3866-3870.
25. Fritsch G, Urban C (1984). Transient encephalopathy during the late course of treatment with high-dose methotrexate. Cancer 53(9): 1849-1851.
26. Glass JP, Lee YY, et al. (1986). Treatment-related leukoen- cephalopathy. A study of three cases and literature review. Medicine 65(3): 154-162.
27. Good CD, Johnsrude IS, et al. (2001). A voxel-based morphometric study of ageing in 465 normal adult human brains. NeuroImage 14: 21-36.
28. Harila-Saari AH, Paakko EL, et al. (1998). A longitudinal magnetic resonance imaging study of the brain in survivors in childhood acute lymphoblastic leukemia. Cancer 83(12): 2608-2617.
29. Heflin LH, Meyerowitz BE, et al. (2005). Re: Cancer as a risk factor for dementia: a house built on shifting sand. J Nat Cancer Inst 97(20): 1550-1551.
30. Hook CC, Kimmel DW, et al. (1992). Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and lev- amisole. Ann Neurol 31(3): 262-267.
31. Inagaki M, Yoshikawa E, et al. (2007). Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109(1): 146-156.
32. Jenkins V, Shilling V, et al. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94(6): 828-834.
33. Johnson SC, Saykin AJ, et al. (2001). Similarities and differences in semantic and phonological processing with age: patterns of functional MRI activation. Aging, Neuropsychol Cogn 8(4): 307-320.
34. Kanard A, Frytak S, et al. (2004). Cognitive dysfunction in patients with small-cell lung cancer: incidence, causes, and suggestions on management. J Support Oncol 2(2): 127-132.
35. Kimmel DW, Wijdicks EF, et al. (1995). Multifocal inflammatory leukoencephalopathy associated with levamisole therapy. Neurology 45(2): 374-376.
36. Kingma A, van Dommelens RI, et al. (2001). Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr 139(3): 413-420.
37. Klunk WE, Engler H, et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55(3): 306-319.
38. Komaki R, Meyers CA, et al. (1995). Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol, Biol Physics 33(1): 179-182.
39. Kwong KK, Belliveau JW, et al. (1992). Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Nat Acad Sci USA 89(12): 5675-5679.
40. Lai S, Hopkins AL, et al. (1993). Identification of vascular structures as a major source of signal contrast in high resolution 2D and 3D functional activation imaging of the motor cortex at 1.5T: preliminary results. Magn Reson Imaging Med 30: 387-392.
41. Le Bihan D, Mangin JF, et al. (2001). Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 13(4): 534-546.
42. Lesnik PG, Ciesielski KT, et al. (1998). Evidence for cerebellar-frontal subsystem changes in children treated with intrathecal chemotherapy for leukemia: enhanced data analysis using an effect size model. Arch Neurol 55(12): 1561-1568.
43. Lien HH, Blomlie V, et al. (1991). Osteogenic sarcoma: MR signal abnormalities of the brain in asymptomatic patients treated with high-dose methotrexate. Radiology 179(2): 547-550.
44. Logothetis NK, Pauls J, et al. (2001). Neurophysiological investigation of the basis of the fMRI signal. Nature 412: 150-157.
45. Mazziotta JC, Toga AW, et al. (2000). Brain Mapping: The Disorders. San Diego, CA: Academic Press.
46. McAllister TW, Sparling MB, et al. (2001). Differential working memory load effects after mild traumatic brain injury. NeuroImage 14(5): 1004-1012.
47. Meyers CA, Byrne KS, et al. (1995). Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12(3): 231-235.
48. Meyers CA, Albitar M, et al. (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104(4): 788-793.
49. Moonen CTW, Bandettini PA (eds.) (2000). Functional MRI. Berlin: Springer.
50. Ogawa S, Menon RS, et al. (1998). On the characteristics of functional magnetic resonance imaging of the brain. Annu Rev Biophys Biomol Struct 27:447-474.
51. Packer RJ, Grossman RI, et al. (1983). High dose systemic methotrexate-associated acute neurologic dysfunction. Med Pediatr Oncol 11(3): 159-161.
52. Pierpaoli C, Jezzard P, et al. (1996). Diffusion tensor MR imaging of the human brain. Radiology 201(3): 637-648.
53. Reddick WE, Shan ZY, et al. (2006). Smaller white- matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer 106(4): 941-949.
54. Reddick WE, Laningham FH, Glass JO, Pui CH (2007). Quantitative morphologic evaluation of magnetic resonance imaging during and after treatment of childhood leukemia. Neuroradiology 49: 889-904.
55. Rosen BR, Buckner RL, et al. (1998). Event-related functional MRI: past, present, and future. Proc Natl Acad Sci USA 95(3): 773-780.
56. Ross MH, Yurgelun-Todd DA, et al. (1997). Age-related reduction in functional MRI response to photic stimulation. Neurology 48(1): 173-176.
57. Saykin AJ, Ahles TA, et al. (2003a). Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8(4): 201-216.
58. Saykin AJ, Ahles TA, et al. (2003b). Gray matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J IntNeuropsychol Soc 9: 246.
59. Saykin AJ, Wishart HA, et al. (2004). Cholinergic enhancement of frontal lobe activity in Mild Cognitive Impairment. Brain 127(7): 1574-1583.
60. Saykin AJ, McDonald BC, et al. (2007). Alterations in Brain Activation during Working Memory in Patients with Breast Cancer: Relation to Treatment Modality, Cancer Status and Task Performance. Available on CD-Rom in Neuroimage, Chicago, IL.
61. Schagen SB, van Dam FSAM, et al. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85(3): 640-650.
62. Shilling V, Jenkins V, et al. (2005). The effects of adjuvant chemotherapy on cognition in women with breast cancer - preliminary results of an observational longitudinal study. The Breast 14:142-150.
63. Silverman DHS, Dy CJ, et al. (2007). Altered fron- tocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 103(3): 303-311.
64. Stemmer S, Stears J, et al. (1994). White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Am J Neuroradiol 15(7): 1267-1273.
65. Tannock IF, Ahles TA, et al. (2004). Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22(11): 2233-2239.
66. Tchen N, Juffs HG, et al. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21 (22): 4175-4183.
67. Toga AW, Mazziotta JC (1996). Brain Mapping: The Methods. San Diego, CA: Academic Press.
68. Van Dam FSAM, Schagen SB, et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Nat Cancer Inst 90(3): 210-218.
69. Van Oosterhout AG, Ganzevles PG, et al. (1996). Sequelae in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Physics 34(5): 1037-1044.
70. Wagner LI, Sweet JJ, et al. (2004). Performance of Cognitively Impaired Oncology Patients and Normal Controls on Functional MRI Tasks. American Society of Clinical Oncology Annual Meeting, New Orleans, LA.
71. Wagner L, Sweet J, et al. (2006). Trajectory of cognitive impairment during breast cancer treatment: a prospective analysis. J Clin Oncol Suppl 24: 8500.
72. Wefel JS, Lenzi R, et al. (2004a). “Chemobrain” in breast carcinoma?: a prologue. Cancer 101(3): 466-475.
73. Wefel JS, Lenzi R, et al. (2004b). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100: 2292-2299.
74. Werring DJ, Clark CA, et al. (1998). The structural and functional mechanisms of motor recovery: complementary use of diffusion tensor and functional magnetic resonance imaging in traumatic injury of the internal capsule. J Neurol Neurosurg Psychiatry 65: 863-869.
75. Werring DJ, Clark CA, et al. (1999). A direct demonstration of both structure and function in the visual system: combining diffusion tensor imaging with functional magnetic resonance imaging. NeuroImage 9(3): 352-361.
76. Wieneke MH, Dienst ER (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 4: 61-66.
77. Wishart HA, Saykin AJ, et al. (2004). Brain activation patterns associated with working memory in relapsing- remitting MS. Neurology 62: 234-238.
78. Yoshikawa E, Matsuoka Y, et al. (2005). No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 92(1): 81-84.